Additional file 2: Figure S2. of Enhanced neuroinvasion by smaller, soluble prions

(a) Western blots show the solubility of two prion strains, 22L (subfibrillar) and 87V (fibrillar). S: supernatant and P: pellet. (b) Quantification of the pellet fraction for all five strains: 87V and 22L in WT mice (n = 5 mice each) and mCWD, ME7, and RML in tga20 mice [n = 3 (mCWD) or 4 mice (ME7, RML)]. *P < 0.05 and **P < 0.01 for 87V versus 22L prions (Student’s unpaired, 2-tailed t-test) and for tga20 mice (one-way ANOVA followed by Tukey multiple comparison test). (TIFF 5 kb

Additional file 5: Figure S5. of Enhanced neuroinvasion by smaller, soluble prions

mCWD fibrillar prions did not neuroinvade from the IT route following exposure to 10-fold higher concentration of PrPSc. (a) Survival curves show that no mice died with detectable mCWD prion plaques. (b) Western blots show no PK-resistant PrPSc in mice inoculated by the IT route. (c) PrP immunohistochemical stains of brain sections from mice exposed IT to 10% mCWD or 10% 87V. n: mock-inoculated brain control. For mCWD mouse groups: n = 10 (1% sonic.), 5 (10% IT), 5 (1% IT), 4 (1% IC). The mice inoculated with 1% mCWD prions IT and IC are the same as those shown in Fig. 1C. Scale bar = 100 μm. (TIFF 5 kb

Pharmacokinetics and tissue biodistribution of iniparib and selected metabolites in the tumor-bearing dog.

<p>Pharmacokinetics and tissue biodistribution of iniparib and selected metabolites in the tumor-bearing dog.</p

Iniparib Dose Escalation cohorts in tumor bearing dogs.

<p>Iniparib Dose Escalation cohorts in tumor bearing dogs.</p

Schedule of patient evaluations and study procedures.

<p>Schedule of patient evaluations and study procedures.</p